Drug Profile


Alternative Names: Fostriecin sodium; Fostrienin; NSC 339638; PD 110161; PD 113270; PD 113271

Latest Information Update: 26 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Alkenes; Cytostatic antibiotics; Pyrones; Small molecules
  • Mechanism of Action Phosphoprotein phosphatase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Ischaemic heart disorders; Solid tumours

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 23 Apr 1999 A study has been added to the Cancer therapeutic trials, adverse events and pharmacokinetics sections
  • 14 Oct 1998 Preclinical development for Ischaemic heart disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top